Compare Air Products & Chemicals, Inc. (APD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs TG Therapeutics Inc — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.88B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Air Products & Chemicals, Inc. is far larger — about 9× TG Therapeutics Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.34% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| APD | TGTX | |
|---|---|---|
Market Cap | $68.88B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $59.06 |
52-Week Low | $230.42 | $26.94 |
Enterprise Value | $86.06B | $7.84B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Air Products and Chemicals (APD) trades at $304.01, down 1.35% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though recent profitability metrics show negative net income margin and ROE. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance, while analyst consensus remains strongly positive with a $346 price target representing 14% upside potential.
The outlook remains constructive given earnings momentum and strategic contract wins, but investors face risks from elevated valuation multiples and recent negative profitability. The stock's technical strength and institutional support provide near-term catalysts, though margin recovery and debt management will be critical for sustained upside.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
